The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors

Published:2016-03 Issue: Volume:93 Page:47-54
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Chen Yu-Mu,Lai Chien-Hao,Chang Huang-Chih,Chao Tung-Ying,Tseng Chia-Cheng,Fang Wen-Feng,Wang Chin-Chou,Chung Yu-Hsiu,Wang Yi-Hsi,Su Mao-Chang,Huang Kuo-Tung,Chen Hung-cheng,Lin Meng-Chih^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference44 articles.

1. Lung cancer incidence trends among men and women—United States, 2005–2009;Henley;MMWR Morb. Mortal. Wkly. Rep.,2014

2. Lung cancer and prognosis in taiwan: a population-based cancer registry;Wang;J. Thorac. Oncol.,2013

3. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC);Chen;Ann. Oncol.,2013

5. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc. Natl. Acad. Sci. U. S. A.,2004

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer;Clinical Lung Cancer;2021-12

2. Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation;Nutrients;2021-10-24

3. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis;Clinical Lung Cancer;2021-09

4. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer;Anticancer Research;2019-03

5. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations;Lung Cancer;2019-01